Welcome to our dedicated page for GILEAD SCIENCES SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences, Inc. filed a quarterly institutional holdings report as an institutional investment manager. The report is a Form 13F Holdings Report, indicating that all reportable holdings for this manager are included. The filing covers 5 reportable positions with an aggregate reported value of $1,648,747,919, rounded to the nearest dollar. One additional manager, Gilead Therapeutics A1 Unlimited Co, is listed as an other included manager in the filing.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson carried out an open-market sale of 3,000 shares of common stock on July 15, 2026 at an average price of $129.9256 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, and he continues to hold 168,646 shares directly.
Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences, reported an open-market sale of 3,000 shares of common stock on 2026-07-15 at a reported price of $129.9192 per share, with trade prices ranging from $129.45 to $130.23. This sale was made under a Rule 10b5-1 trading plan adopted on February 20, 2025, and she now directly holds 121,234 Gilead shares.
Johanna Mercier plans to sell 3,000 shares of Gilead common stock through Morgan Stanley Smith Barney LLC on 07/15/2026 on NASDAQ, for an aggregate value of $389,757.60.
The shares come from Performance Shares acquired from the issuer on 02/04/2025. Over the prior three months, Mercier sold 3,000 shares on 06/15/2026 for $371,762.10 and 28,000 shares on 05/15/2026 for $3,676,197.75.
Shareholder Andrew Dickinson filed a notice of proposed sale of up to 3,000 shares of GILD common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an estimated aggregate market value of $389,776.80, planned on or about 07/15/2026 on NASDAQ.
The 3,000 shares were acquired as Performance Shares from the issuer on 01/31/2024. In the past three months he sold 3,000 common shares for $396,810.00 on 05/15/2026 and 3,000 common shares for $376,200.00 on 06/15/2026.
Gilead Sciences Chairman & CEO Daniel O'Day disclosed open-market sales of 15,000 shares of Common Stock. On July 1, 2026, he sold 3,100 shares at an average price of $127.075 and 11,900 shares at $126.0897, according to the Form 4.
The sales were executed under a Rule 10b5-1 trading plan adopted on February 25, 2026, indicating they were pre-arranged rather than newly timed decisions. Footnotes state sale prices for the reported transactions ranged from $125.59 to $127.44, with full trade-by-trade details available on request.
Gilead Sciences executive Johanna Mercier reported open-market sales of 3,000 shares of Gilead common stock. The transactions occurred on June 15, 2026 at prices ranging from $122.79 to $125.40 per share, as described in the footnotes.
The filing states that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. After the transactions, Mercier directly holds 124,234 shares of Gilead common stock, according to the reported post-transaction balance.
Gilead Sciences Chief Financial Officer sells shares under trading plan
Gilead Sciences CFO Andrew D. Dickinson reported an open-market sale of 3,000 shares of common stock at $125.40 per share. After the sale, he directly holds 171,646 shares. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice for proposed sales of 9,000 common shares by Andrew Dickinson. The filing lists three sales dates — 03/16/2026, 04/15/2026, and 05/15/2026 — each for 3,000 shares, with dollar amounts shown per sale.
Morgan Stanley Smith Barney LLC filed a Rule 144 notice relating to 3,000 shares of Common Stock of GILD (listed as performance shares dated 02/04/2025) that are proposed to be sold by the issuer under Rule 144. The filing also lists recent sales by Johanna Mercier: 28,000, 3,000, and 3,000 shares on 05/15/2026, 04/15/2026, and 03/16/2026, respectively, with stated proceeds for each sale.